Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Curepro Parenterals Limited, was an unlisted public company incorporated on 19 April, 2013. It is classified as a public limited company and is located in , Telangana. It's authorized share capital was INR 20.00 cr and the total paid-up capital was INR 13.31 cr.
The current status of Curepro Parenterals Limited is - Amalgamated.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
9.29%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Madan Mohan Reddy Mettu | 01284266 | 11 years |
| Director | Sivakumaran Meenakshisunderam | 01284320 | 9 years |
| Director | Sarath Chandra Reddy Penaka | 01628013 | 11 years |
| Director | Bhanu Murthy Chavali | 08434178 | 5 years |
| Kmp | Srinivasarao Devathi | <HIDDEN> | 5 years |
| Kmp | Venkat Reddy Kupireddy | <HIDDEN> | 5 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| AUROBINDO PHARMA LTD |
Active
|
58.1 Cr | 2 | Telangana |
| OREMSI PLASTICS PRIVATE LIMITED |
Strike Off
|
1.3 L | 1 | Telangana |
| AURONEXT PHARMA PRIVATE LIMITED |
Amalgamated
|
125.0 Cr | 2 | Telangana |
| THERANYM BIOLOGICS PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| AUROZEST PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| AURO VACCINES PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| CREST EXCIPIENTS LLP |
Strike Off
|
1.3 L | 1 | Telangana |
| EUGIA STERILES PRIVATE LIMITED |
Active
|
44.2 Cr | 2 | Telangana |
| EUGIA PHARMA SPECIALITIES LIMITED |
Active
|
621.0 Cr | 2 | Telangana |
| CURATEQ BIOLOGICS PRIVATE LIMITED |
Active
|
100.0 Cr | 2 | Telangana |
| PRAVESHA INDUSTRIES PRIVATE LIMITED |
Active
|
10.0 Cr | 1 | Telangana |
| EUGIA SEZ PRIVATE LIMITED |
Active
|
4.0 Cr | 2 | Telangana |
| TRIDENT LIFE SCIENCES LIMITED |
Amalgamated
|
1.6 L | 2 | Telangana |
| APL RESEARCH CENTRE LIMITED |
Amalgamated
|
12.3 Cr | 1 | Telangana |
| AUROZYMES LIMITED |
Amalgamated
|
5.0 L | 1 | Telangana |
| AUROACTIVE PHARMA PRIVATE LIMITED |
Active
|
100.0 Cr | 1 | Telangana |
| AURO PEPTIDES LIMITED |
Active
|
265.9 Cr | 1 | Telangana |
| TERGENE BIOTECH LIMITED |
Active
|
45.0 Cr | 1 | Telangana |
| AUROBINDO PHARMA FOUNDATION |
Active
|
1.0 L | 2 | Telangana |
| APL HEALTHCARE LIMITED |
Active
|
216.0 Cr | 1 | Telangana |
| ROSA AVENUES INDIA PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| AXIS CLINICALS INDIA LIMITED |
Strike Off
|
5.0 L | 1 | Telangana |
| PVR CHEMPHAR PRIVATE LIMITED |
Active
|
2.2 Cr | 1 | Telangana |
| AURYN LABS LIMITED |
Strike Off
|
5.0 L | 1 | Telangana |
| SARATH PENAKA ENTERPRISES LLP |
Active
|
1.0 L | 1 | Telangana |
| SHREAS INDUSTRIES LIMITED |
Active
|
400.0 Cr | 1 | Telangana |
| AUROBINDO ANTIBIOTICS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Andhra Pradesh |
The incorporation date of CUREPRO PARENTERALS LIMITED is 19 April, 2013
The authorized share capital of CUREPRO PARENTERALS LIMITED is INR ₹ 20.0 Cr.
The paid-up capital of CUREPRO PARENTERALS LIMITED is INR ₹ 13.3 Cr.
The registered address of CUREPRO PARENTERALS LIMITED is PLOT NO.2, MAITRIVIHAR AMEERPET HYDERABAD Telangana - 500038
The CIN number of CUREPRO PARENTERALS LIMITED is U24232TG2013PLC087101.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
